{
  "report_rows": [
    {
      "kpi": "Total revenue",
      "prediction": "BEAT",
      "answer": "pred ~$11.86B vs. cons $11.73B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Operating diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.62 vs. cons $1.60",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Growth Portfolio revenue",
      "prediction": "BEAT",
      "answer": "pred ~$7.15B vs. cons $7.04B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 total revenue",
      "prediction": "UNCHANGED",
      "answer": "guide ~$46.0\u2013$47.5B vs. cons $47.45B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 non-GAAP EPS",
      "prediction": "UNCHANGED",
      "answer": "guide $6.05\u2013$6.35 vs. cons $6.34",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 Eliquis growth",
      "prediction": "UNCHANGED",
      "answer": "guide +10%\u201315% vs. cons ~+12.9%",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -2.5,
  "day1_confidence": "LOW",
  "day5_residual_pct": -3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 maintained FY guidance after a beat likely fails to support further revisions",
  "day5_confidence": "LOW"
}